老年急性淋巴细胞白血病患者的异基因造血干细胞移植:来自SFGM-TC的注册研究
该注册研究纳入2010至2022年间316例接受异基因造血干细胞移植的≥60岁急性淋巴细胞白血病患者,中位年龄63.8岁。3年总生存率46%,无进展生存率41%,非复发死亡率23%,复发率36%,无移植物抗宿主病无复发生存率30%。多因素分析显示进展期疾病和非Ph+ ALL与更差生存相关,而年龄本身不影响结局。
要点
- ≥60岁ALL患者alloHSCT后3年OS为46%,PFS为41%,NRM为23%,RI为36%,GRFS为30%。
- 进展期疾病患者OS和PFS更差,HR为1.79(95%CI 1.22-2.64),p=0.0032。
- 非Ph+ ALL亚型与更差结局相关,HR为1.99(95%CI 1.42-2.79)。
核心结论
- 该研究表明alloHSCT对老年ALL患者是可行选择,因为年龄本身不影响结局,但进展期疾病和非Ph+ ALL与显著更差的生存相关。
研究设计与样本
- SFGM-TC注册研究,纳入2010至2022年间接受alloHSCT的316例≥60岁ALL患者,中位年龄63.8岁(范围60-75.8)。
主要发现
- 3年OS为46%(95%CI 40%-53%),3年PFS为41%(95%CI 35%-48%),3年NRM为23%(95%CI 18%-28%),3年RI为36%(95%CI 31%-42%),3年GRFS为30%(95%CI 25%-37%)。
- 多因素分析确认进展期疾病患者OS和PFS更差,HR为1.79(95%CI 1.22-2.64),p=0.0032。
- ALL亚型显著影响结局,非Ph+ ALL的HR为1.99(95%CI 1.42-2.79)。
- 49.8%患者为Ph+ B-ALL,70.9%在移植时处于第一次完全缓解(CR1)。
- 供者类型:52.1%为无关供者,26.3%为匹配相关供者(MRD),17.7%为单倍体相合供者;64.6%接受减低强度预处理(RIC),35.8%接受全身照射(TBI)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There are very limited data regarding the outcomes of elderly patients with acute lymphoblastic leukemia (ALL) who undergo allogeneic hematopoietic stem cell transplantation (alloHSCT). A total of 316 ALL patients aged ≥ 60 years who underwent alloHSCT between 2010 to 2022 were identified in the SFGM-TC registry. The primary objective was to evaluate progression-free survival (PFS), non-relapse mortality (NRM), relapse incidence (RI), and graft-versus-host disease (GvHD)-free relapse-free survival (GRFS), as well as their risk factors. The median age was 63.8 years (range 60-75.8), 49.8% of patients had Philadelphia-positive B-ALL (Ph + ALL), and 70.9% were in first complete remission (CR1) at transplantation. The donor was an unrelated donor in 52.1%, a matched related donor (MRD) in 26.3%, and a haplo-identical donor in 17.7%. Reduced-intensity conditioning (RIC) was administered to 64.6% of patients, while total body irradiation (TBI) was used in 35.8%. The 3-year overall survival (OS) was 46% (95% CI 40%-53%). The 3-year PFS, NRM, RI, and GRFS were 41% (95% CI 35%-48%), 23% (95% CI 18%-28%), 36% (95% CI 31%-42%), and 30% (95% CI 25%-37%), respectively. Multivariable analyses confirmed poorer OS and PFS in patients with advanced disease, with an HR of 1.79 (95% CI 1.22-2.64), p = 0.0032. Additionally, the ALL subtype significantly impacted outcomes, with an HR of 1.99 (95% CI 1.42-2.79) for non-Ph + ALL. This study suggests that alloHSCT is a viable option for elderly ALL patients, as age itself did not impact outcomes. However, advanced disease and non-Ph + ALL were associated with significantly worse survival.
引用
- Chalandon Y, Devillier R, Boumendil A, et al. Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Am J Hematol. 2025. PMID: 40326583. doi:10.1002/ajh.27701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。